Osteopontin expression in lung cancer.

[1]  A. Craig,et al.  Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. , 1994, Cancer research.

[2]  A. Gazdar.  Molecular markers for the diagnosis and prognosis of lung cancer , 1992, Cancer.

[3]  Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. , 1995, Molecular and cellular biology.

[4]  A. Chambers,et al.  Recombinant GST‐human osteopontin fusion protein is functional in RGD‐dependent cell adhesion , 1994, Journal of cellular biochemistry.

[5]  D. Denhardt,et al.  Osteopontin: a protein with diverse functions , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  A. Chambers,et al.  Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. , 1994, The Journal of biological chemistry.

[7]  A. Chambers,et al.  Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. , 1992, Anticancer research.

[8]  A. Craig,et al.  Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. , 1988, Biochemical and biophysical research communications.

[9]  A. Chambers,et al.  Site‐directed mutagenesis of the arginine‐glycine‐aspartic acid sequence in osteopontin destroys cell adhesion and migration functions , 1995, Journal of cellular biochemistry.

[10]  A. Craig,et al.  Secreted phosphoprotein mrna is induced during multi‐stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts , 1990, International journal of cancer.

[11]  V. Castronovo,et al.  Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. , 1995, The American journal of pathology.

[12]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[13]  O. Mcbride,et al.  cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). , 1990, Genomics.

[14]  C. Perruzzi,et al.  Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. , 1989, Anticancer research.

[15]  S. Hirota,et al.  Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[16]  J. Minna.  The molecular biology of lung cancer pathogenesis. , 1993, Chest.

[17]  L. Su,et al.  Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. , 1995, Oncogene.

[18]  W. Butler,et al.  The nature and significance of osteopontin. , 1989, Connective tissue research.

[19]  A. Chambers,et al.  Osteopontin: Role in Cell Signalling and Adhesion , 1995 .

[20]  T. Tong,et al.  Cancer statistics, 1993 , 1993, CA: a cancer journal for clinicians.

[21]  E. Manseau,et al.  Osteopontin expression and distribution in human carcinomas. , 1994, The American journal of pathology.

[22]  A. Chambers,et al.  Overcoming obstacles to metastasis ‐ defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells , 1994, Journal of cellular biochemistry.

[23]  H. Cantor,et al.  Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. , 1993, Critical reviews in immunology.

[24]  B. Berse,et al.  Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. , 1994, Oncogene.

[25]  J. Roth.  Molecular events in lung cancer. , 1995, Lung cancer.